Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Small fiber neuropathy (SFN) is the most common cause of neuropathic pain in peripheral
neuropathies, with a prevalence of at least 53/100.000. Patients with SFN may have
excruciating pain and current anti-neuropathic and other pain drugs do not relief pain
substantially.
Several studies suggested an immunological basis in SFN and case studies have reported
efficacy of treatment with intravenous immunoglobulin (IVIg) in patients with SFN. It is
therefore conceivable that immunological mechanisms play a role in idiopathic SFN (I-SFN).
However, to date no randomized controlled study with IVIg in patients with SFN has been
performed. The aim of the current study is to investigate the efficacy and safety of IVIg in
patients with I-SFN in a randomized, double-blind, placebo-controlled study.
The objective of the study is to evaluate the efficacy of IVIg treatment (4 courses of
treatment, 3 weeks apart) compared to placebo on pain alleviation.